General
Preferred name
Balsalazide
Synonyms
BALSALAZID ()
Balsalazido ()
Balsalazide Sodium ()
Balsalazide (sodium hydrate) ()
Balsalazide disodium dihydrate ()
Colazal, Giazo ()
BALSALAZIDE DISODIUM ()
Balsalazida ()
Balsalazine ()
Colazal ()
Colazide ()
Balsalazide disodium anhydrous ()
BX-661A ()
Balsalazide disodium salt dihydrate ()
BX661A ()
NSC-760046 ()
Giazo ()
Balsalazide sodium ()
Balsalazide-d4 ()
P&D ID
PD009593
CAS
80573-04-2
82101-18-6
150399-21-6
Tags
available
prodrug
drug
Approved by
FDA
First approval
2000
Drug Status
approved
investigational
Max Phase
4.0
Drug indication
Ulcerative colitis
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].
PRICE
51
DESCRIPTION
Balsalazide sodium hydrate is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].
PRICE
53
DESCRIPTION
Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. Balsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis.
(Enamine Bioactive Compounds)
DESCRIPTION
Balsalazide (Balsalazido) is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Balsalazide sodium hydrate (Balsalazide disodium) is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.Balsalazide sodium hydrate is a new 5-aminosalicylic acid (5-ASA) containing prodrug. High dose Balsalazide sodium hydrate(3.0 g twice daily) was superior in maintaining remission in patients with ulcerative colitis compared with a low dose (1.5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated [1]. Balsalazide sodium hydrate is approved for the treatment of mild-to-moderate active UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile, with the added advantages of greater efficacy of remission induction and rapidity of onset [2].
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
NCATS Inxight Approved Drugs
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
60
Molecular Weight
357.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
4
Rotatable Bonds
7
Ring Count
2
Aromatic Ring Count
2
cLogP
2.71
TPSA
148.65
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.56
Structural alerts
1
azo_A(324)
[#7;!R]=[#7]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target
Interleukin
STAT
Lipoxygenase
ALOX5, PPARG, PTGS1, PTGS2
Interleukin Related
Immunology & Inflammation related,Interleukins,STAT
Indication
ulcerative colitis
MOA
cyclooxygenase inhibitor
Pathway
Immunology/Inflammation
JAK/STAT Signaling
Stem Cells
Metabolism
Stem Cell/Wnt
Source data
